KOS, Jiří, Gilles DEGOTTE, Dominika PINDJAKOVA, Tomáš STRHÁRSKY, Timotej JANKECH, Tomáš GONĚC, Pierre FRANCOTTE, Michel FREDERICH and Josef JAMPILEK. Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides. Molecules. Basel: MDPI, 2022, vol. 27, No 22, p. 1-10. ISSN 1420-3049. Available from: https://dx.doi.org/10.3390/molecules27227799.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides
Authors KOS, Jiří (203 Czech Republic, guarantor, belonging to the institution), Gilles DEGOTTE, Dominika PINDJAKOVA, Tomáš STRHÁRSKY (703 Slovakia, belonging to the institution), Timotej JANKECH, Tomáš GONĚC (203 Czech Republic, belonging to the institution), Pierre FRANCOTTE, Michel FREDERICH (203 Czech Republic) and Josef JAMPILEK (203 Czech Republic).
Edition Molecules, Basel, MDPI, 2022, 1420-3049.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.600
RIV identification code RIV/00216224:14110/22:00127693
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/molecules27227799
UT WoS 000887320300001
Keywords in English cinnamanilides; antiplasmodial activity; Plasmodium; structure-activity relationships
Tags 14110512, podil, rivok, ÚChL
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 27/1/2023 10:52.
Abstract
Due to the urgent need of innovation in the antimalarial therapeutic arsenal, a series of thirty-seven ring-substituted N-arylcinnamanilides prepared by microwave-assisted synthesis were subjected to primary screening against the chloroquine-sensitive strain of P. falciparum 3D7/MRA-102. The lipophilicity of all compounds was experimentally determined as the logarithm of the capacity factor k, and these data were subsequently used in the discussion of structure-activity relationships. Among the screened compounds, fourteen derivatives exhibited IC50 from 0.58 to 31 µM, whereas (2E)-N-(4-bromo-2-chlorophenyl)-3-phenylprop-2-enamide (24) was the most effective agent (IC50 = 0.58 µM). In addition, (2E)-N-[2,6-dibromo-4-(trifluoromethyl)- phenyl]-3-phenylprop-2-enamide (36), (2E)-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-phenylprop- 2-enamide (18), (2E)-N-(2-bromo-5-fluorophenyl)-3-phenylprop-2-enamide (23), and (2E)-3-phenyl-N-(3,4,5-trichlorophenyl)prop-2-enamide (33) demonstrated efficacy in the IC50 range from 2.0 to 4.3 µM, comparable to the clinically used standard chloroquine. The results of a cell viability screening performed using THP1-Blue™ NF-κB cells showed that none of these highly active compounds displayed any significant cytotoxic effect up to 20 μM, which makes them promising Plasmodium selective substances for further investigations.
PrintDisplayed: 25/7/2024 22:14